Form 4: Taysha Gene Therapies Exec Trades Shares

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, reports transactions involving common stock and employee stock options.

Summary

• Nagendran Sukumar, who holds the positions of Director, President and Head of R&D at Taysha Gene Therapies, Inc., has reported transactions on April 10, 2026.
• A total of 19,021 shares of common stock were acquired at a price of $1.71 per share.
• Additionally, 200,000 shares of common stock were disposed of at a weighted average price of $4.46 per share, with individual sale prices ranging from $4.335 to $4.625.
• Following these transactions, Sukumar beneficially owns 1,136,410 shares of common stock directly.
• A derivative security transaction involved the acquisition of 19,021 employee stock options, with an exercise price of $1.71, acquired under a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While there's a significant sale of shares, it's conducted under a pre-established trading plan, and there's also an acquisition of shares and options, balancing the overall sentiment.

Positives

• Acquisition of 19,021 shares of common stock at a favorable price of $1.71.
• The acquisition of employee stock options at an exercise price of $1.71 suggests potential for future gains if the stock price increases.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-determined strategy for managing stock holdings.

Negatives

• Disposal of 200,000 shares of common stock at a price significantly higher than the acquisition price, indicating a profit-taking move.
• The weighted average sale price of $4.46 per share suggests a substantial amount of value was realized by the reporting person.

Risks

• The disposal of a significant number of shares could be interpreted as a lack of confidence in near-term stock appreciation by a key executive.
• The Rule 10b5-1 plan, while providing a defense against insider trading allegations, still involves the sale of company stock by management.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the acquisition of stock options under a Rule 10b5-1 plan implies an expectation of future stock performance to realize value from these options.

Management Comments

• The transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
• The price reported for the disposed shares is a weighted average price, with sales occurring at prices ranging from $4.335 to $4.625 inclusive.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions. The use of a Rule 10b5-1 plan by a senior executive like Nagendran Sukumar is common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific details of the acquisition and disposal prices provide insight into the executive's perspective on the stock's valuation at different points in time.

Stakeholder Impact

• Shareholders may view the sale of shares by a senior executive with mixed feelings, potentially as a sign of profit-taking or a lack of conviction, though the Rule 10b5-1 plan mitigates some concerns.
• Employees may be influenced by the executive's trading activity, though the acquisition of options could be seen as a positive signal for future company performance.

Next Steps

• The remaining portion of the employee stock options will vest and become exercisable in 36 equal monthly installments following January 2, 2025, subject to continuous service.
• The reporting person may continue to execute transactions under the Rule 10b5-1 trading plan.

Key Dates

Keywords

Taysha Gene Therapies, TSHA, Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, Rule 10b5-1, Executive Transactions, SEC Filing